CytomX Therapeutics, Inc.
CTMX
$3.79
-$0.09-2.32%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -98.26% | -82.16% | -25.71% | 22.80% | 43.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -98.26% | -82.16% | -25.71% | 22.80% | 43.17% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -98.26% | -82.16% | -25.71% | 22.80% | 43.17% |
| SG&A Expenses | 11.31% | -19.19% | -21.12% | 21.59% | -28.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.36% | -25.89% | -40.58% | -5.07% | -24.98% |
| Operating Income | -242.16% | -483.56% | 84.78% | 94.06% | 3,017.33% |
| Income Before Tax | -239.70% | -344.45% | 98.60% | 70.43% | 893.60% |
| Income Tax Expenses | -12.90% | -4.92% | 23.53% | 26.53% | -94.20% |
| Earnings from Continuing Operations | -240.44% | -348.06% | 97.64% | 70.58% | 2,155.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -240.44% | -348.06% | 97.64% | 70.58% | 2,155.20% |
| EBIT | -242.16% | -483.56% | 84.78% | 94.06% | 3,017.33% |
| EBITDA | -236.09% | -444.36% | 88.25% | 89.76% | 15,176.67% |
| EPS Basic | -179.01% | -227.89% | 98.44% | 60.62% | 2,036.89% |
| Normalized Basic EPS | -163.12% | -226.06% | 99.16% | 60.53% | 845.21% |
| EPS Diluted | -179.55% | -233.53% | 98.50% | 60.62% | 2,520.24% |
| Normalized Diluted EPS | -163.12% | -226.35% | 99.16% | 61.60% | 845.21% |
| Average Basic Shares Outstanding | 97.90% | 93.91% | 52.07% | 6.21% | 5.13% |
| Average Diluted Shares Outstanding | 97.90% | 93.66% | 52.07% | 5.47% | 5.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |